Download pptx - Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer


Early Chemo+ADT: A debate in one slide – a need for randomized phase 3 trial


The CHAARTED Hypothesis


E3805 – CHAARTED Treatment


Key Eligibility Criteria


Study Endpoints


Statistical Design: History of CHAARTED<br />Intent to treat analysis, 80% power 1-sided alpha=2.5% to detect 33% improvement in median OS (with all versions)


Results:


Patient characteristics






Primary endpoint: Overall survival


Causes of Death


OS by extent of metastatic disease at start of ADT


ADT + Docetaxel benefited all subgroups


Secondary Endpoints


Therapy beyond progression


Chemotherapy Doses Given


Non-Hematologic Toxicity (%)


Hematologic Toxicity (%)


Conclusion


Clinical interpretation


Designed and conducted by:
